Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QCC374 · 1 trial · 1 indication
Number of Participants with Adverse Events
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo comparator |
| QCC374 | EXPERIMENTAL | Single and multiple ascending doses of QCC374 |
| Name | Type | Description |
|---|---|---|
| QCC374 | DRUG | Single and multiple ascending doses of QCC374 |
| Placebo | DRUG | Placebo comparator |
Inclusion Criteria: 1. Written informed consent must be obtained before any assessment is performed. 2. Healthy male and female subjects age 18 to 55 years of age included, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory...
QCC374 is an investigational small molecule being developed by Novartis AG. It is currently in Phase 1 clinical development. The drug has been studied in healthy subjects, with one completed trial assessing its safety, tolerability, and pharmacokinetics.
QCC374 is being studied for use in healthy subjects. It is an investigational drug in early clinical development, and its intended therapeutic use has not been established. The completed Phase 1 trial focused on safety, tolerability, and pharmacokinetics.
QCC374 is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker NVS. The company conducted a Phase 1 clinical trial to evaluate the drug's safety and tolerability in healthy volunteers.
QCC374 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is no longer in active clinical trials according to available data.
QCC374 was studied in a single Phase 1 clinical trial with the identifier NCT02245828. This was a first-in-human study to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of QCC374. The trial enrolled 66 healthy subjects in the United Kingdom and has been completed.
QCC374 is the only name provided for this investigational drug. No alternative names have been identified in the available information. It is a small molecule being developed by Novartis AG.